<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04629430</url>
  </required_header>
  <id_info>
    <org_study_id>HSR 200296</org_study_id>
    <nct_id>NCT04629430</nct_id>
  </id_info>
  <brief_title>Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT</brief_title>
  <acronym>HCTDiet</acronym>
  <official_title>Effects of Prebiotics on Gut Microbiome in Patients Undergoing Stem Cell Transplants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see whether hematopoietic stem cell transplant (HSCT)&#xD;
      patients can consistently eat a diet rich in prebiotics. This type of diet may be helpful in&#xD;
      maintaining diversity in the gastrointestinal (GI) system and therefore potentially&#xD;
      decreasing risk of other GI problems.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Maintaining gastrointestinal (GI) microbiome diversity has been shown to improve treatment&#xD;
      related mortality in HSCT patients. Interventions to improve GI microbial diversity could be&#xD;
      beneficial to this patient population. Diets rich in prebiotics have been shown to increase&#xD;
      gut microbial diversity and improve symptoms in other gastrointestinal diseases. Prebiotics&#xD;
      are non-digestible carbohydrates that promote growth of commensal organisms in the gut by&#xD;
      providing nutrition. Some examples are brown rice, green apples, and tomatoes. Our theory is&#xD;
      that consuming a diet rich in prebiotics pre- and during the first 100 days following HSCT&#xD;
      will help to reduce acute graft versus host disease (aGVHD) overall, and specifically acute&#xD;
      GI GVHD, and clostridium difficile (C.Diff). Participants will be encouraged to eat at least&#xD;
      2 servings of a prebiotic-rich food from time of admission for HSCT through 100 days&#xD;
      following HSCT and will be clinically monitored, including for acute GVHD, acute GI GVHD and&#xD;
      C.Diff. Stool samples will be collected from all participants about once every 4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of participants ingesting the required diet</measure>
    <time_frame>From initiation of conditioning regimen for HSCT through 100 days following HSCT</time_frame>
    <description>Frequency of participants reporting ingesting at least 2 servings of prebiotics on ≥ 80% of study days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of acute GVHD (aGVHD) and acute GI GVHD</measure>
    <time_frame>Within the first 100 days following HSCT</time_frame>
    <description>Stage and grade of aGVHD (allogeneic HSCT participants only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of CDiff infection</measure>
    <time_frame>Within the first 100 days following HSCT</time_frame>
    <description>Number of people diagnosed with CDiff during the time frame</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient weight</measure>
    <time_frame>From initiation of conditioning regimen for HSCT through 100 days following HSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days to neutrophil engraftment</measure>
    <time_frame>From initiation of conditioning regimen for HSCT through 100 days following HSCT</time_frame>
    <description>Absolute neutrophil count &gt;1000 for 1 day or &gt; 500 for 3 consecutive days</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Non Hodgkin Lymphoma</condition>
  <condition>Acute Lymphocytic Leukemia</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Hodgkin Disease</condition>
  <condition>Myelofibrosis</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myeloproliferative Neoplasm</condition>
  <condition>Sickle Cell Disease</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Prebiotic diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 servings a day of pre-biotics every day from start of conditioning regimen for HSCT through 100 days following HSCT</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pre-biotic foods/drinks</intervention_name>
    <description>2 servings per day</description>
    <arm_group_label>Prebiotic diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Agreement to adhere to Lifestyle Considerations(prebiotic diet) throughout study&#xD;
             duration&#xD;
&#xD;
          2. Adults (≥18 yrs of age)&#xD;
&#xD;
          3. Able to provide informed consent&#xD;
&#xD;
          4. Are willing/able to incorporate the required foods in their diet&#xD;
&#xD;
          5. Eligible, suitable and planning to undergo a stem cell transplant:&#xD;
&#xD;
               1. Either allogeneic or autologous&#xD;
&#xD;
               2. With any conditioning regimen (e.g. both myeloablative and reduced intensity&#xD;
                  conditioning)&#xD;
&#xD;
               3. Matched related, matched unrelated, haplo-identical and cord blood transplants&#xD;
                  will be included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients undergoing a second allogeneic or autologous transplant or an allogeneic&#xD;
             transplant after an autologous transplant.&#xD;
&#xD;
          2. Anticipation of requirement of broad spectrum antibiotics 1 week prior to admission&#xD;
             for HSCT (through HSCT)&#xD;
&#xD;
          3. Patients with any prior history of C.Diff infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Indumathy Varadarajan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gianna Strand</last_name>
    <phone>434 243 6377</phone>
    <email>grs9zj@hscmail.mcc.virginia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Danyelle Coley</last_name>
    <phone>(434) 982-5027</phone>
    <email>JCS6RZ@hscmail.mcc.virginia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianna Strand</last_name>
      <phone>434-243-6377</phone>
      <email>grs9zj@hscmail.mcc.virginia.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 10, 2020</study_first_submitted>
  <study_first_submitted_qc>November 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Indumathy Varadarajan, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>hematopoietic stem cell transplant</keyword>
  <keyword>stem cell transplant</keyword>
  <keyword>bone marrow transplant</keyword>
  <keyword>GI microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

